Table 2.

Overall survival from randomized trials of elderly GBM patients in setting of COVID-19–associated mortality

Study Author, Year of publication	Arms	Hazard Ratio (95% CI)				Median OS, mo (95% CI)
		Baseline	Low Risk	Medium Risk	High Risk	Baseline	Low Risk	Medium Risk	High Risk
Malmstrom et al, 2012	RT-30 (ref)	–	–	–	–	6.11 (5.21–7.66)	6.05 (5.08–7.66)	5.21 (4.04–6.43)	3.96 (2.90–5.73)
	RT-10	0.86 (0.65–1.15)	0.86 (0.64–1.14)	0.81 (0.61–1.08)	0.80 (0.60–1.06)	7.60 (6.59–9.18)	7.53 (6.59–9.04)	7.28 (5.95–8.41)	6.15 (5.14–7.66)
	TMZ	0.71 (0.53–0.95)	0.69 (0.52–0.93)	0.61 (0.46–0.82)	0.54 (0.40–0.73)	8.27 (6.96–9.70)	8.12 (6.96–9.70)	8.27 (6.96–9.70)	8.27 (6.96–9.70)
Perry et al, 2017	RT15 (ref)	–	–	–	–	7.60 (7.04–8.48)	7.56 (6.97–8.33)	6.97 (5.96–7.65)	5.62 (4.48–6.70)
	RT15 + TMZ	0.66 (0.55–0.78)	0.66 (0.55–0.79)	0.69 (0.58–0.82)	0.73 (0.61–0.86)	9.32 (8.35–10.4)	9.23 (8.25–10.3)	8.31 (7.56–9.65)	7.13 (5.84–8.14)
Roa et al, 2004	RT-30 (ref)	–	–			5.49 (4.19–8.36)	5.17 (4.19–8.36)	4.24 (2.95–6.80)	3.40 (2.20–5.70)
	RT-15	0.92 (0.59–1.41)	0.90 (0.58–1.39)	0.88 (0.57–1.36)	0.91 (0.59–1.39)	5.71 (4.68–8.36)	5.71 (4.68–8.36)	5.24 (3.12–8.06)	4.26 (2.39–5.84)
Wick et al, 2012	RT-30 (ref)	–	–	–	–	9.41 (8.16–10.7)	9.25 (7.90–10.3)	7.61 (6.49–9.48)	6.10 (4.20–7.84)
	TMZ	1.09 (0.84–1.42)	1.05 (0.81–1.36)	0.85 (0.66–1.09)	0.68 (0.53–0.87)	8.46 (7.44–10.4)	8.43 (7.15–10.0)	8.46 (7.44–10.4)	8.46 (7.44–10.0)
Keime-Guibert et al, 2007	SC (ref)	–	–	–	–	3.61 (2.89–4.87)	3.61 (2.89–4.87)	3.61 (2.89–4.87)	3.64 (2.89–4.87)
	RT-28	0.45 (0.28–0.73)	0.46 (0.29–0.74)	0.55 (0.34–0.88)	0.66 (0.42–1.06)	6.50 (5.60–8.03)	6.50 (3.90–8.03)	6.27 (2.89–7.76)	3.21 (2.37–7.13)

Baseline: Estimates from reconstructed IPLD, without incorporation of COVID-19 risk.

Low Risk: Case fatality rate = 10%, infection risk per fraction = 1%.

Medium Risk: Case fatality rate = 20%, infection risk per fraction = 5%.

High Risk: Case fatality rate = 30%, infection risk per fraction = 10%.

ref: Reference arm.

SC: Supportive Care.